- Home
- ANVS vs ASRT Comparison
ANVS vs ASRT Comparison
Compare ANVS & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | ASRT |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 76.0M |
| IPO Year | 2019 | 2004 |
Fundamental Metrics
Financial Performance| Metric | ANVS | ASRT |
|---|---|---|
| Price | $2.59 | $13.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $13.50 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 358.2K | 42.2K |
| Earning Date | 03-16-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.39 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $118,713,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.11 | $0.51 |
| 52 Week High | $5.50 | $13.90 |
Technical Indicators
Market Signals| Indicator | ANVS | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 66.87 |
| Support Level | $2.29 | $0.69 |
| Resistance Level | $2.63 | N/A |
| Average True Range (ATR) | 0.22 | 0.65 |
| MACD | 0.02 | 0.14 |
| Stochastic Oscillator | 36.05 | 78.95 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.